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Abstract
Background
Prostate cancer (PCa) is the most common cancer among men in western countries. While
active surveillance is increasingly utilized, the majority of patients are currently treated with
radical prostatectomy. In order to avoid over-treatment, there is an indisputable need for reli-
able biomarkers to identify the potentially aggressive and lethal cases. Nuclear intermediate
filament proteins called lamins play a role in chromatin organization, gene expression and
cell stiffness. The expression of lamin A is associated with poor outcome in colorectal can-
cer but to date the prognostic value of the lamins has not been tested in other solid tumors.
Methods
We studied the expression of different lamins with immunohistochemistry in a tissue micro-
array material of 501 PCa patients undergoing radical prostatectomy and lymph node dis-
section. Patients were divided into two staining categories (low and high expression). The
correlation of lamin expression with clinicopathological variables was tested and the associ-
ation of lamin status with biochemical recurrence (BCR) and disease specific survival
(DSS) was further analyzed.
Results
Low expression of lamin A associated with lymph node positivity (p<0.01) but not with other
clinicopathological variables and low expression had a borderline independent significant
association with DSS (HR = 0.4; 95% CI 0.2–1.0; p = 0.052). Similarly, low lamin C expres-
sion associated with poorer survival (HR = 0.2; 95% CI 0.1–0.6; p = 0.004). Lamin B1
expression did not associate with clinicopathological variables but high expression indepen-
dently predicted BCR in multivariable Cox regression analysis (HR = 1.8; 95% CI 1.1–2.9; p
= 0.023). Low expression of lamin B2 correlated with lymph node positivity (p<0.01) and
predicted unfavorable DSS (HR = 0.4; 95% CI 0.2–1.0; p = 0.047).
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Conclusions
These results suggest differential roles for lamins in PCa progression. Reduced amounts of
lamin A/C and B2 increase risk for lymph node metastasis and disease specific death possi-
bly through increased nuclear deformability while high expression of lamin B1 predicts dis-
ease recurrence.
Introduction
Prostate cancer (PCa) is the most common malignancy among men and a remarkable public
health challenge in Western countries. In United States, more than 230 000 new cases and 29
000 PCa related deaths was expected to be diagnosed in 2014 [1]. The major risk factors for
PCa include age, positive family history and African-American race [2]. The majority of
patients are currently treated with radical prostatectomy and/or radiotherapy while active sur-
veillance may be beneficial for low risk patients. In most of the cases, the disease is local and
only ~7% of patients treated with radical prostatectomy (RP) die from PCa during a 15-year
follow-up [3]. Furthermore, it seems clear that the treatment of low-grade cancer (Gleason
score 6 or below) confers no survival benefit when compared to other causes of death. The use
of prostate-specific antigen (PSA) has revolutionized the diagnostics of PCa during the past 25
years and more recently systematic PSA screening has been shown to decrease PCa-related
mortality [4]. However, PSA lacks the specificity to detect clinically significant cancers and the
drawback is over-diagnosis of cancers that would not have effect on the quality and expectancy
of life if left untreated [5]. This in turn leads to overtreatment with potential side effects. In
order to avoid over-treatment, there is an indisputable need for reliable biomarkers to identify
the potentially aggressive and lethal cases from those that remain local.
Nuclear lamins are type V intermediate filament (IF) proteins. They are the major compo-
nents of the nuclear lamina, a fibrous meshwork of proteins that underlies the inner nuclear
membrane [6]. Lamins are devided into two subgroups, A-type and B-type lamins. A single
gene, LMNA, encodes all A-type lamins that include lamin A, lamin C, a testis-specific isoform
lamin C2 and minor isoform lamin AΔ10. The major B-type lamins, lamin B1 and lamin B2,
are encoded by two genes (LMNB1 and LMNB2, respectively) [7]. In addition, a germ cell spe-
cific lamin B3 is generated from LMNB2 through alternative splicing [8]. At least one B-type
lamin is expressed in all metazoan cells, while A-type lamins are primarily expressed in differ-
entiated cells [7].
The lamins have multiple functions in the cell nucleus. They provide mechanical support
for the nucleus and play a role in DNA replication and repair, transcription, chromatin organi-
zation and gene regulation [7]. Numerous mutations in LMNA cause a group of inherited
human diseases or disorders commonly called the laminopathies. These include, for example,
cardiac and skeletal myopathies, lipodystrophies, peripheral neuropathy and premature aging
disease known as progeria syndrome [9]. While the fundamental pathobiology of these diseases
is mostly poorly understood, abnormalities of nuclear shape (e.g. herniations and lobulations)
are commonly reported in cells carrying disease-associated lamin mutations. Interestingly, sim-
ilar morphological changes of the nucleus are frequently observed in cancer cells including
PCa cells [10]. Therefore, it is possible that altered expression and modifications in lamins con-
tribute malignant transformation in cancer cells [11].
Only a few retrospective studies have substantiated the association between altered lamin
expression and patient outcome. In stage I-III colorectal cancer (CRC), the patients with lamin
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A expressing tumors had significantly increased risk to die from CRC when compared to
patients with lamin A negative tumors [12]. Based on in vitro studies, the authors further con-
cluded that this is due to increased cell motility, invasiveness and stem cell-like phenotype pro-
moted by lamin A/C. On the contrary, Belt et al. reported that loss of lamin A/C in stage II-III
colon cancer is associated with disease recurrence [13]. In nodal diffuse large B-cell lymphoma
inactivation of lamin A/C gene by CpG island promoter hypermethylation is associated with
poor survival [14].
The role of lamins in PCa has been studied more recently. Using mass spectrometry (MS)
and immunohistochemistry, Skvortsov et al. reported decreased expression of lamin A in low
grade (Gleason score 6) tumors relative to paired samples from histologically normal tissue
while an increased expression was detected in high risk (Gleason score 8) tumors [15]. Further-
more, lamin A/C is overexpressed at the invasive front of PCa tissue and promotes cell growth,
migration and invasion through the PI3K/AKT/PTEN pathway under culture conditions [16].
The expression of B-type lamins, on the other hand, is increased in cancerous prostate tissue
and strongly correlates with Gleason score [17]. MS analysis further suggests that lamin B1 is
hyperphosphorylated in androgen independent PC-3 cells [18]. Interestingly, chromosomal
regions associated with PCa risk localize to nuclear lamin B-deficient microdomains (LDMD)
that exhibit reduced gene transcription (10). While the nature of these structures is currently
unclear, the frequency of LDMDs correlates with PCa cell line aggressiveness, cell motility and
Gleason grade [10]. In summary, lamins undergo significant alterations during malignant
transformation but to date it is unclear whether any of these changes have predictive value in
PCa, especially in high grade cancer.
In the present study we studied the expression of different lamins in PCa in detail using tis-
sue microarray (TMA) material covering over 500 patients treated with radical prostatectomy
and lymph node dissection. Our results show that decreased expression of A-type lamins is
associated with elevated risk for lymph node metastasis and disease specific death while
increased expression of lamin B1 is associated with BCR and local spread. Additionally, low
lamin B2 expression predicted higher risk of PCa mortality. We also discuss the potential cell
biological mechanisms and their significance for clinical risk stratification.
Materials and Methods
Tissue material
Paraffin embedded formalin fixed tissue material from 501 patients operated with radical pros-
tatectomy and limited pelvic lymphadenectomy in the Turku University Central Hospital
between January 2000 and September 2005 were used for constructing the TMA blocks as pre-
viously described [19]. In brief, three to twelve (median 3.0) adjacent cores of 1 mm in diame-
ter were obtained from the index carcinoma lesion that was considered the most significant
(based on the Gleason grade pattern, the volume of cancer lesion and/or extra-prostatic exten-
sion). In addition, one core from histologically benign prostate tissue was obtained from the
same patient. These tissue cores were transferred from the donor blocks to the recipient TMA
blocks that contained in total 63 cores per block including control tissues from normal liver.
All cases in the final TMA blocks were graded based on the International Society of Urological
Pathology updated Gleason grading system [20]. At the time of surgery, no consent was
obtained from the participants for this specific study. At the time of the study, the use of tissue
material and the corresponding clinicopathological and follow-up data was approved by the
Ethics Committee of the Hospital District of the Southwest Finland (130/180/2008) and the
National Authority for Welfare and Health (Valvira 394/05.01.00.06/2009) according to the
national legislation. Patient information was anonymized and de-identified prior to analysis.
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Clinical data
None of the patients received androgen deprivation or radiotherapy prior to or immediately
after the surgery. The follow-up was conducted by digital rectal examination and post-opera-
tive PSA measurement at least three times during the first year after the surgery and at least
once a year during the following years. Of the 501 patients, 158 (31%) had a biochemical recur-
rence (BCR) defined as PSA level of 0.2 μg/L or above after the surgery.
The staging of the PCas was performed according to the WHO pTNM classification system
[21]. 28 patients (4.4%) died from PCa during the follow-up, while 39 (7.8%) died of other causes.
Due to long time interval between operations, each patient’s original clinical Gleason score (GS)
was re-evaluated by experienced genitourinary pathologist according to the current Gleason
grading system criteria [20] using hematoxylin-eosin sections from the original radical prostatec-
tomy specimens. This score was used in the survival analyses and is presented in Table 1.
Table 1. Clinicopathological variables of the patient cohort (n = 501).
Variable Number of patients
Age
<60 years 169 (34%)
60–65 years 187 (37%)
>65 years 143 (29%)
PSA group (μg/L)
<10 306 (61%)
10–20 116 (23%)
>20 38 (8%)
pT-categorya
pT2 209 (42%)
pT3a 160 (32%)
pT3b 52 (10%)
Gleason group
<7 181 (36%)
7 199 (40%)
>7 96 (19%)
Extraprostatic extension
Yes 203 (41%)
Surgical margin
Positive 190 (38%)
Lymph node status
N+ 21 (4%)
BCR
Yes 157 (31%)
Alive 444 (89%)
Death due Pca 20 (4%)
Death, other 37 (7%)
Follow-up time (months)
Median 91
Range 1–167
a Pathological T (pT) category refers to the stage of primary tumor in the TNM tumor staging system.
pT2 = Tumor conﬁned within prostate, pT3a = Extracapsular extension, pT3b = tumor invading seminal
vesicle(s).
doi:10.1371/journal.pone.0140671.t001
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Immunohistochemistry and microscopy
In order to perform immunohistochemical (IHC) assessment, paraffin was first removed with
xylene and the sections were rehydrated with graded series of alcohol. All the antibodies were
tested on prostate TMA test blocks prior to use in the final TMAmaterial in order to optimize
the dilution and the most suitable pre-treatment. Epitope unmasking was carried out by micro-
waving the tissue slides in either Tris-HCl buffer (pH 9; lamin B1, B2 and C antibodies) or Cit-
rate based buffer (pH 6; lamin A antibody) for 10 min. The primary antibodies used were
mouse monoclonal anti-lamin A (1:1000, clone 133A2, Abcam), goat polyclonal anti-lamin B1
(1:4000, C-20, Santa Cruz), mouse monoclonal anti-lamin B2 (1:500, LN43, Abcam) and rabbit
polyclonal anti-lamin C (1:150, RalC, Novus). Due to variation in the staining between differ-
ent patches of lamin C antibody, only 199 patients stained with the same patch were included
in the final statistical analysis. The stainings were carried out using Ventana automated stain-
ing machine and the primary antibodies were detected with Vectastain anti-mouse or anti-goat
HRP-conjugated secondary antibodies. The slides were counterstained with hematoxylin and
observed with Olympus BX60 microscope (Olympus Optical Co., Ltd., Tokyo, Japan).
The TMA slides were graded visually for IHC grades, without the knowledge of clinico-
pathological characteristics of the patients. The staining intensities of each core were graded as
0 (no specific staining in carcinoma cells, intense staining in benign glands and stromal cells), 1
(low intensity nuclear lamina staining in carcinoma cells, more intense staining in benign
glands or stromal cells), 2 (moderate intensity and clearly visible lamina in carcinoma cells, yet
more intense staining in benign glands and stromal cells) or 3 (high intensity lamina staining
equivalent to, or exceeding the intensity of normal glands and stromal cells). Patients whose
tissue samples were stained poorly (based on internal controls) or detached from the slides dur-
ing staining process were excluded from the analysis. The mean intensity values of 3 or more
carcinoma cores were determined for each patient and eventually the patients were dichoto-
mized into low (IHC grade 0 and 1) and high (IHC grades 2 and 3) expressing groups for fur-
ther statistical analysis (except for lamin B1 and C, see Table 2). Dichotomization was based on
the distribution of different subgroups for each lamin staining in order to have comparable
groups with sufficient number of patients (see Table 2).
Statistical analysis
The statistical analysis was performed with SPSS 20 (IBM). The correlations between clinico-
pathological variables and biomarkers were analyzed using chi-square test. The correlation
between mean lamin expression in benign and cancerous prostate tissue from the same patients
were analyzed with independent-samples T test. The Kaplan-Meier method, Log-rank test and
Cox proportional hazards regression model were used to analyze the association of staining
intensity to outcome. For outcome analyses, the time for BCR-free survival was calculated
from the day of surgery to the day of detection of PSA of 0.2 μg/L or above. The disease specific
survival time was calculated from the date of surgery to the date of the last follow-up visit or
death.
The survival analyses were performed for the entire cohort (except for lamin C, see above)
and for a high risk subpopulation including patient with GS 7–10 tumors. All statistical tests
were two-sided and p-values0.05 were considered statistically significant.
Results
In order to study whether expression of different lamins is associated with PCa biochemical
progression and disease specific survival (DSS), TMAmaterial containing at least triplicate
cancerous samples and one morphologically benign sample from 501 radically operated PCa
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patients was stained with antibodies detecting different lamins (A, C, B1 and B2) and the stain-
ing intensities were compared to clinicopathological variables. The demographics of patients
are presented in the Table 1. In the Kaplan-Meier estimation analysis, the well-known clinico-
pathological features such as high GS and preoperative PSA, T category, extraprostatic exten-
sion (EPE) and seminal vesicle invasion (SVI) were statistically significantly associated with
BCR indicating that our cohort is highly representative to test the correlation between the pro-
teins of interest and patient outcome (data not shown). Similarly, high GS, T category, positive
surgical margin, EPE, SVI and lymph node (LN) positivity predicted shortened time for dis-
ease-specific death (data not shown). In multivariable Cox regression analysis that took other
prognostic markers into account, high GS, preoperative PSA and T-category were independent
predictors of BCR (Table 3) while high GS, T-category and LN positivity predicted death from
PCa (Table 4).
Staining with lamin A specific antibody showed that lamin A is expressed in both basal and
luminal epithelial cells of normal prostatic glands and is enriched at the nuclear lamina region
as expected (Fig 1A). However, there were significant differences in staining intensities between
carcinomas from individual patients (from grade 0 to 3). The mean staining intensities of carci-
noma cell nuclei were significantly higher when compared to normal epithelium in benign
samples from the same patients (paired-samples t-test; mean staining intensities +/- SEM 1.97
+/-0.03 and 1.45+/-0.03 for carcinoma and benign, respectively, p<0.001). Low lamin A
expression (grade 0–1) was statistically significantly associated with lymph node positivity
(Pearson Chi-Square test, p = 0.009) but no other clinicopathological variables tested. In
Kaplan-Meier estimation analysis, there was no correlation between lamin A expression and
BCR (data not shown). When DSS was used as an end point, a trend between low lamin A
expression and poor outcome was seen in the whole population but this difference failed to
show statistical significance (Fig 1B; p = 0.27). However, in the subpopulation of GS>6 tumors
with potentially aggressive behavior, low lamin A expression was statistically significantly asso-
ciated with poor outcome (Fig 1C; p = 0.044). These results suggest that diminished amount of
lamin A may promote lymphovascular invasion and progression of potentially metastatic
disease.
Table 2. The distribution of expression for each lamin in the patient cohort.
Number of patients
Marker GS* group Low expression High expression Total
Lamin A IHC grade 0–1 IHC grade 2–3
Entire group 251 (52.0%) 232 (48.0%) 483
Subgroup (GS>6) 141 (50.0%) 141 (50.0%) 282
Lamin C IHC grade 0 IHC grade 1–3
Entire group 41 (22.9%) 138 (77.1%) 179
Subgroup (GS>6) 22 (21.4%) 81 (78.6%) 103
Lamin B1 IHC grade 0–2 IHC grade 3
Entire group 142 (30.3%) 327 (69.7%) 469
Subgroup (GS>6) 82 (30.0%) 191 (70.0%) 273
Lamin B2 IHC grade 0–1 IHC grade 2–3
Entire group 169 (37.5%) 282 (62.5%) 451
Subgroup (GS>6) 88 (33.5%) 175 (66.5%) 263
*GS = Gleason score
doi:10.1371/journal.pone.0140671.t002
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Lamin C is another major A-type lamin encoded by LMNA through alternative splicing.
This isoform is 92 amino acids shorter than lamin A and carries a unique C-terminal tail that is
removed from pre-lamin A during posttranslational modification. The staining with lamin C
antibody (detecting the lamin C specific C-terminal tail domain only) showed that lamin C is
similarly expressed and present at the nuclear lamina in both normal basal and luminal epithe-
lial cells as well as in the majority of (but not all) carcinomas with low to moderate intensities
(S1A Fig). A paired T-test showed that the mean staining intensities for lamin C were signifi-
cantly higher in carcinoma samples (1.30+/-0.06) relative to normal epithelium (1.04+/-0.05,
p = 0.001). There was no correlation between lamin C expression and clinicopathological vari-
ables (data not shown). In the Kaplan-Meier analysis, we found no correlation between lamin
C expression and BCR (data not shown) similar to lamin A. There was a trend between unde-
tectably low lamin C expression (grade 0) and less favorable DSS when patients with all the dif-
ferent Gleason groups were studied (S1B Fig; p = 0.14). Moreover, in the GS>6 subpopulation
the patients with lamin C negative tumors (grade 0) had statistically significantly higher risk to
Table 3. Uni- andmultivariate Cox regression analysis for risk of biochemical recurrence. In addition to entire study cohort, a subpopulation of patients
with GS>6 tumor was analyzed separately.
Entire group Subgroup (GS>6)
Univariate Multivariate Univariate Multivariate
Variable HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Gleason score
<7 ref ref na na
7 1.9 1.2–3.0 <0.003* 1.3 0.8–2.3 0.32 ref ref
>7 4.8 3.0–7.5 <0.001* 2.6 1.5–4.7 0.001* 2.4 1.7–3.5 <0.001* 2.0 1.0–3.3 <0.002*
sPSA
Continuous 1.06 1.05–1.08 <0.001* 1.04 1.02–1.06 <0.001* 1.05 1.04–1.07 <0.001* 1.04 1.02–1.06 <0.001*
pT categorya
pT2 ref ref ref ref
pT3 3.1 2.1–4.6 <0.001* 2.2 1.3–3.5 0.002* 2.3 1.4–3.7 0.001* 1.7 1.0–2.9 0.053
Lamin A
Low ref ref ref ref
High 1.0 0.7–1.3 0.85 0.81 0.5–1.2 0.29 0.9 0.6–1.3 0.58 0.7 0.5–1.1 0.15
Lamin B1
Low ref ref ref ref
High 1.5 1.0–2.2 0.04* 1.8 1.1–2.9 0.023* 1.7 1.0–2.7 0.036* 1.6 0.9–2.9 0.077
Lamin B2
Low ref ref ref ref
High 1.1 0.8–1.6 0.48 0.95 0.6–1.4 0.81 0.95 0.6–1.4 0.82 0.85 0.5–1.4 0.49
Lamin C
Low ref ref ref ref
High 1.0 0.5–1.9 0.88 0.70 0.3–1.7 0.41 1.1 0.5–2.5 0.9 0.58 0.2–1.7 0.32
HR, hazard ratio (describes the relative risk of the event at any given time based on comparing the group with the reference group); 95% CI, 95%
conﬁdence interval (A 95% conﬁdence interval means that 95% of the values of an unobservable parameter of interest would set in the interval if the
experiment is repeated); na, not available; ref, reference
* Signiﬁcant p-value
a Pathological T category refers to the stage of primary tumor in the TNM tumor staging system. pT2 = Tumor conﬁned within prostate, pT3 = Tumor
invading extraprostatic tissue and/or seminal vesicle(s).
doi:10.1371/journal.pone.0140671.t003
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die from PCa (S1C Fig; p = 0.009). These results suggest that lamin A and C, both produced
from LMNA gene, may have similar biological effects in malignant transformation of PCa.
The expression of lamin B1 is generally detected in all the eukaryotic cells and its loss has
severe consequences during embryogenesis as highlighted with developmental abnormalities
of lung and brain and early perinatal death in LMNB1 knockout mice [22]. In our material, all
the histologically benign samples showed mild to moderate staining intensity for lamin B1. All
the carcinoma samples were lamin B1 positive as well (Fig 2A) but 65% of the carcinomas
showed high expression (grade 3) of lamin B1. Paired t-test revealed that there was significantly
more lamin B1 staining in carcinomas relative to normal benign samples (2.7+/-0.03 vs. 1.7
+/-0.03, p<0.001). No significant correlation was found between lamin B1 expression and
Table 4. Uni- andmultivariate Cox regression analysis for risk of prostate cancer-specific death. In addition to entire study cohort, a subpopulation of
patients with GS>6 tumor was analyzed separately.
Entire group Subgroup (GS>6)
Univariate Multivariate Univariate Multivariate
Variable HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Gleason score
<7 ref ref na na
7 8.8 1.0–71.0 0.042* 9.3 1.1–77.4 0.039* ref ref
>7 28.9 3.7–224.7 0.001* 37.6 4.8–296.2 0.001* 3.3 1.4–8.0 0.008* 3.0 0.9–9.3 0.063
sPSA
Continuous 1.80 0.99–3.24 0.051 1.02 0.98–1.07 0.31
pT categorya
T2 ref ref
T3 60.3 1.4–2688.4 0.034* 41.4 0.6–2642.6 0.079
N categoryb
N0 ref ref
N1 6.5 2.5–16.9 <0.001* 5.5 2.1–14.6 0.001*
Lamin A
Low ref ref ref ref
High 0.3 0.2–1.5 0.27 0.4 0.16–1.0 0.052 0.4 0.1–1.0 0.052 0.4 0.2–1.2 0.11
Lamin B1
Low ref ref ref ref
High 1.5 0.4–5.1 0.55 1.6 0.5–5.7 0.44 1.4 0.4–5.1 0.57 1.7 0.5–6.1 0.40
Lamin B2
Low ref ref ref ref
High 0.5 0.2–1.2 0.11 0.41 0.17–0.99 0.047* 0.4 0.2–1.0 0.058 0.6 0.2–1.6 0.29
Lamin C
Low ref ref ref ref
High 0.4 0.2–1.2 0.095 0.2 0.1–0.6 0.004* 0.3 0.1–0.8 0.023* 0.3 0.1–0.9 0.03*
HR, hazard ratio (describes the relative risk of the event at any given time based on comparing the group with the reference group); 95% CI, 95%
conﬁdence interval (A 95% conﬁdence interval means that 95% of the values of an unobservable parameter of interest would set in the interval if the
experiment is repeated); na, not available; ref, reference
* Signiﬁcant p-value
a pathological tumor (pT) category refers to the stage (i.e. size and extent) of primary tumor in the TNM tumor staging system. pT2 = Tumor conﬁned
within prostate, pT3 = Tumor invading extraprostatic tissue and/or seminal vesicle(s).
b N category describes in TNM system weather (N1) or not (N0) the cancer has spread to the regional lymph nodes.
doi:10.1371/journal.pone.0140671.t004
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Fig 1. Low lamin A expression in PCa predicts unfavorable DSS. (A) Representative examples of TMA slides stained for lamin A with
immunohistochemistry. Low and high power field images from both low and high expressing tumors are shown. (B-C) Kaplan-Meier analysis shows a trend
between low lamin A expression and poor DSS in the entire cohort (B; p = 0.27). However, in the subpopulation of patients with Gleason score >6 tumors,
there is statistically significant difference (C; p = 0.044).
doi:10.1371/journal.pone.0140671.g001
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clinicopathological variables tested. In the Kaplan-Meier analysis, high expression of lamin B1
was associated with BCR in the whole cohort (Fig 2B; p = 0.038) and in the subpopulation of
GS>6 (p = 0.034, data not shown). However, there was no correlation between lamin B1
expression and DSS in either the whole cohort (Fig 2C; p = 0.55) or in the subpopulation of
patients with GS>6 tumors (p = 0.57, data not shown). In multivariable Cox regression analy-
sis high lamin B1 expression remained an independent predictor of BCR in the entire cohort
when adjusted for preoperative PSA and Gleason grade (HR 1.8, 95% CI 1.1–2.9, p = 0.023;
Table 3). These results suggest that high expression of lamin B1, for unknown reasons,
increases risk for PCa recurrence but has no significant effect on PCa survival.
Lamin B2 was expressed in all the normal and malignant prostate glands (Fig 3A). However,
similar to other lamins, there was statistically significantly higher IHC intensity of lamin B2 in
the cancerous glands relative to normal benign glands (1.74+/-0.03 vs. 1.48+/-0.03, p<0.001).
Low lamin B2 expression was associated with lymph node positivity (Chi-square; p = 0.005)
and there was a trend between low lamin B2 expression and T category (p = 0.076) and EPE
(p = 0.098). In Kaplan-Meier analysis, there was no correlation between lamin B2 expression
and BCR (data not shown). However, When DSS was used as an end point, there was a trend
between low lamin B2 expression and poor DSS in the whole cohort (Fig 3B; p = 0.099) and a
borderline statistical significance in GS>6 subpopulation (Fig 3C; p = 0.051). These results
show that lamin B1 and lamin B2 predict different outcome in PCa which may be due to differ-
ential roles in cancerous prostate cells.
Discussion
The nuclear lamins are highly conserved among species and phylogenetic analysis suggests that
they represent ancestors of whole IF protein family [23]. There is accumulating evidence that
lamins not only support physical shape of the nucleus but also contribute several fundamental
nuclear functions such as genome organization and transcription through interactions with
chromatin and multiple transcription factors [7]. Dysfunction in these mechanisms may have
deleterious effects in vivo as evidenced by various hereditary human diseases due to lamin
mutations [9]. However, the role and alterations of lamins in malignant diseases are less well
understood.
In the present study we investigated the expression of different lamins in PCa and their
potential use in estimation of patient outcome using an extensive TMAmaterial and a detailed
clinical patient data with a median follow-up time of more than 8 years. While the expression
of all the major lamins was detected in prostatic epithelium, the statistical analysis revealed
some interesting changes that are relevant in the light of recent in vitro findings about lamin
function. Swift et al. have shown that the amount of lamin A and the ratio of A- and B-type
lamins correlates with tissue stiffness (e.g. muscle has more lamin A than brain) to stabilize
nucleus and chromatin from physical stress [24]. Furthermore, low levels of A-type lamins
increase nuclear deformability and enhance cell migration through microfluidic constrictions
in vitro [25] and in vivo in a mouse tumor model [26]. This is consistent with our results show-
ing that reduced amounts of lamin A/C are associated with lymph node metastasis and unfa-
vorable DSS, presumably due to increased lymphovascular invasion. The association between
low lamin A expression and unfavourable DSS was statistically significant in Kaplan-Meier
analysis carried out on patients with potentially aggressive GS>6 disease (Fig 1C). However, in
the multivariate Cox regression analysis, that also takes other clinicopathological variables into
account, lamin A slightly failed to reach statistical significance (p = 0.052, Table 4) suggesting
that it is not an independent predictive marker different from lamin B1. The data from others
suggest that lamin A is overexpressed in the invasive front in PCa and may increase local
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Fig 2. High lamin B1 expression in PCa predicts increased risk for BCR. (A) Representative examples of TMA slides stained for lamin B1 with
immunohistochemistry. Low and high power field images from both low and high expressing tumors are shown. (B-C) Kaplan-Meier analysis indicates that
high lamin B1 expression predicts shorter time to BCR in the whole cohort (B; p = 0.038) but has no correlation with DSS (C; p = 0.55).
doi:10.1371/journal.pone.0140671.g002
Nuclear Lamins in Prostate Cancer Progression
PLOS ONE | DOI:10.1371/journal.pone.0140671 October 15, 2015 11 / 16
Fig 3. Low lamin B2 expression in PCa predicts shortened DSS. (A) Representative examples of TMA slides stained for lamin B2 with
immunohistochemistry. Low and high power field images from both low and high expressing tumors are shown. (B-C) Kaplan-Meier analysis shows a trend
between low lamin B2 expression and shortened DSS in the entire cohort (B; p = 0.099). In the subpopulation of patients with Gleason score >6 tumors,
Kaplan-Meyer analysis slightly fails to show statistically significant difference but a strong trend is seen (C; p = 0.051).
doi:10.1371/journal.pone.0140671.g003
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migration and invasion [16]. If this were the case, one would expect that high expression levels
of lamin A/C correlate with BCR but we were unable to confirm such phenomenon. These dif-
ferences may be, at least partly, due to variation in sampling. Despite the fact that we obtained
three triplicate samples from the index tumor, these tissue cores represent overall tumor
expression levels and were not intentionally targeted to areas of invasive front.
The results from this and other studies suggest that the changes in lamin expression and
their impact on tumor biology and clinical outcome may be complex and organ-specific. Previ-
ously the prognostic value of lamins in cancer progression has been established in colorectal
cancer (CRC) where lamin A expression predicts poor outcome when compared to lamin A
negative cancers [12]. However, little is known about the prognostic role of lamins in other
solid tumors and our results suggest opposite role for lamin A in PCa progression (Fig 1C). A
fundamental difference between these two types of adenocarcinomas is that 30% of CRCs were
virtually devoid of lamin A [12] but at least some lamin A expression was detected in all PCas
included in the present study. The results from in vitro studies suggest that silencing of lamin
A may actually sensitize the cells for mechanical stress and reduce cell survival [26]. Therefore,
presence of lamin A in CRC may mechanically protect the migrating cancer cells and reduce
tumor cell death when compared to lamin A negative tumors while in the case of PCa moder-
ately low amount of lamin A may simultaneously provide an ideal nuclear deformability and
sufficient protection against mechanical stress in invading cells.
A- and B-type lamins have differential roles in normal cells. While A-type lamins are mostly
expressed in terminally differentiated cells, one or both of the B-type lamins are expressed in
all animal cells. Mice lacking lamin B1, lamin B2 or both have defects in lung and brain devel-
opment and these mice die at birth suggesting an essential developmental function [22]. Inter-
estingly, increased production of one B-type lamin does not rescue the loss of the other B-type
lamin indicating that lamin B1 and B2 have also differential cellular functions [27]. Similarly,
our results suggest differential roles for lamin B1 and B2 in PCa progression. PCa tissues con-
tained significantly more lamin B1 than benign tissues from the same patients. High lamin B1
expression associated with BCR in the entire cohort, as well as in the GS>6 subpopulation (Fig
2B), and in multivariable Cox regression analysis lamin B1 appeared an independent prognos-
tic factor for BCR (Table 3). Nevertheless, there was no statistically significant correlation
between lamin B1 expression and DSS (Fig 2C and Table 4). Although our cohort is relatively
large, it is important to notice that only 4.4% of patients died from PCa during the follow-up
while 31% showed BCR. In most cases, the latter may be due to minimal local residual tumor
that has no impact on DSS after salvage radiation therapy [28]. Therefore, high lamin B1
expression is more likely promoting local growth and/or proliferation, rather than enabling
metastatic behavior through lymphovascular invasion. In support for this, a recent study has
shown that moderate reduction of lamin B1 in cancer cells delays cell cycle progression [29].
Furthermore, silencing of lamin B1 in normal diploid WI-38 lung cells causes replicative senes-
cence while overexpression increases the proliferation rate [30]. Coradeghini et al. have previ-
ously reported that lamin B1 expression correlates with GS and could be used as a biomarker
in tumor differentiation and prognostics [17]. We were unable to confirm the correlation with
GS but even more importantly our results clearly suggest that lamin B1 is an independent pre-
dictor that could be used to determine the risk of local growth and proliferation.
Little is known about role of lamin B2 and its association with cancer. In the present study,
low lamin B2 expression predicted LN positivity, similar to lamin A and C. Additionally, there
was a trend between low expression of lamin B2 and less favorable DSS (Fig 3B and 3C) but lit-
tle in common with lamin B1. Recently, Kuga et al. provided evidence that lamin B2 plays a
role in mitotic spindle formation [31]. Furthermore, knockdown of lamin B2 resulted in chro-
mosomal instability in CRC cells [31]. Although a more precise role of lamin B2 in spindle
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function still needs to be addressed it is tempting to speculate that PCa tumors with low
amounts of lamin B2 are more prone to chromosomal instability, aneuploidy and eventually
progression towards aggressive and potentially metastatic phenotype.
In summary, our results suggest that lamins have differential roles in PCa progression and
that they could be used as prognostic biomarkers in PCa diagnostics and risk stratification. For
example, immunohistochemical lamin A staining from prostatic biopsy material might help in
identifying the high risk patient who would benefit from lymph node dissection. However, the
use semi-quantitative methods like immunohistochemistry in routine clinical diagnostic work
may be challenging and would require sensitive and well validated control samples. Due to rel-
atively high frequency of BCR and low frequency of mortality in PCa, further studies with even
more extensive and multi-centered patient cohorts would be needed to validate the prognostic
role of lamins in PCa. In addition, it would be of great interest to study the expression of A-
and B-type lamins in PCa LN and distant metastases in the following studies.
Supporting Information
S1 Fig. Low lamin C expression in PCa predicts shortened DSS. (A) Representative examples
of TMA slides stained for lamin C with immunohistochemistry. Low and high power field
images from both low and high expressing tumors are shown. (B-C) Kaplan-Meier analysis
shows a trend between low lamin C expression and shortened DSS in the entire cohort (B;
p = 0.14). However, in the subpopulation of patients with Gleason score>6 tumors, there is
statistically significant difference (C; p = 0.009).
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